CTLA4 and acute kidney injury: The anti-PD-1 plus chemotherapy, anti-PD-1 plus anti-CTLA-4, and anti-PD-1 plus targeted therapy were associated with relatively higher rate of RAEs, grade 3–5 RAEs, AKI, and grade 3–5 AKI than other regimens.